神经分泌生物科学 NBIX 深 沪
等待开盘 08-17 09:30:00 美东时间
152.72
+1.900
+1.26%
华盛通- 最 高153.42
- 今 开149.72
- 成交量 130.51万股
- 最 低 148.775
- 昨 收 150.82
- 总市值 155.24亿
- 52周最高 186.12
- 市盈率 静 32.71
- 换手率 1.28%
- 52周最低 122.1375
- 委 比 52.99%
- 总股本 1.02亿
- 历史最高 186.12
- 量 比 0.95
- 振 幅 3.08%
- 历史最低 5.42
- 每 手 1
- 风险率 14.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline). The San Diego-based compa...
08-12 23:57
Neurocrine slips as safety issues linked to Vykat XR resurface
Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added with its acquisition of Soleno Therapeu...
08-12 19:29
Regeneron, Tenet leads top healthcare companies with highest earnings beats
As corporate earnings season progresses, investors are tracking sector performance metrics to gauge underlying healthcare demand and corporate efficiency. For the healthcare sector, spanning critical ...
08-12 18:54
Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity
Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study e...
08-07 20:33
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocri...
08-07 20:30
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) fell sharply on Friday after a late-stage trial setback for Novo Nordisk (NVO) called into question the mechanisms underlying their expe...
08-01 02:09
Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $204
Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $200 to $204.
07-31 17:12
